Back to search results
Vadim S. Koshkin
4.9 out of 5 (166)
Vadim S. Koshkin

Vadim S. Koshkin, MD

Genitourinary Medical Oncology

Genitourinary Medical Oncology Clinic
1825 Fourth St., Sixth Floor,
San Francisco, CA 94158
+1 more location
(415) 476-4616
4.9 out of 5 (166)
Virtual visits available
4.9 out of 5 (166)
Virtual visits available
Genitourinary Medical Oncology Clinic
1825 Fourth St., Sixth Floor,
San Francisco, CA 94158
+1 more location
(415) 476-4616

Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are.

In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors.

After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network.

A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time.

  • Board Certifications

    American Board of Internal Medicine, Medical Oncology, 2018

    American Board of Internal Medicine, Internal Medicine, 2015

  • Fellowships

    Cleveland Clinic-GME, Hematology - Oncology, 2018

  • Residencies

    University of Michigan Hospitals and Health Centers, Internal Medicine, 2015

  • Internship

    University of Michigan Hospitals and Health Centers, Internal Medicine, 2013

  • Degree

    University of Chicago Division of the Biological Sciences The Pritzker School of Medicine, 2012

  • Languages

    English

Each cancer patient is unique and deserves unique care. This means extra attention to personal needs but also individualized attention to treatment.

Conditions I specialize in

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    166 Ratings
    About our process
    May 25, 2025
    Dr Koshkin is an excellent compassionate caring and supportive physician. He takes the time needed to make sure I understand everything necessary for my treatment
    Apr 30, 2025
    I wish you had more choices... I would give Dr. Koshkin a 10+
    Mar 22, 2025
    Dr Koshkin is Excellent!!
    Mar 04, 2025
    Dr koshkin. Has been treating me for two yearsHe is very thorough and shows concern
    Feb 26, 2025
    Love Dr. Koshkin!
    Feb 19, 2025
    We feel very fortunate to have this care team.
    Feb 06, 2025
    Dr. Koshkin is friendly, kind and caring. We discuss, at length, my options going forward and any concerns he may have. He is always very positive and I never feel like he's rushing the call or uninterested.
    Dec 13, 2024
    Dr Koshkin is the consummate professional, a tribute to ucsf
    Nov 23, 2024
    Dr Koshkin and his associates are fantastic!
    Oct 09, 2024
    Overall rating of care provider = exceptional
    Oct 02, 2024
    Dr. Koshkin and his staff are patient, respectful and very helpful not only from the top flight medical care, but also caring about getting any related help that is needed.
    Oct 02, 2024
    Dr. Koshkin is always great.
    Aug 28, 2024
    Dr. Koshkin is a fabulous physician. Very caring, Knowledgeable and thorough In both his questions and answers
    Aug 07, 2024
    Always a positive experience.
    Jul 31, 2024
    Always great to speak with Dr Koshkin
    May 30, 2024
    Very knowledgeable and informative
    Mar 18, 2024
    How can I be critical of someone who has helped me live 8+ years with Stage 4 prostate cancer. I have not only lived longer than I thought, but my quality of life could not be better, for my age.
    Mar 06, 2024
    I am extremely happy with the discussion process and followed with a written summary of next steps.
    Jan 05, 2024
    Dr Koshkin was very patient with our questions and concerns.
    Oct 05, 2023
    Very knowledgeable, open, kind and caring
    Sep 09, 2023
    Dr Koshkin is wonderful.

    Selected research

    See all research
    Decorative Caduceus

    A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolum...

    Disease recurrence is defined as any of the following: - Local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes) - Urinary tract recurrence of UC (excluding low-grade no...

    Recruiting

    Decorative Caduceus

    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV...

    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the National C...

    Recruiting

    Decorative Caduceus

    Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...

    The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...

    Recruiting

    Decorative Caduceus

    Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...

    If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. Per Invest...

    Recruiting

    Contact me

    Share